Serum tumour markers in renal failure

Area of Science:

• Nephrology
• Clinical Chemistry
• Oncology

Background:

• Chronic renal failure (CRF) affects numerous physiological processes.
• Tumour markers are utilized in various clinical contexts, but their role in renal disease requires further elucidation.
• Uraemia may influence the levels of certain biomarkers.

Purpose of the Study:

• To evaluate the clinical utility of six tumour markers in patients with chronic renal failure.
• To compare tumour marker levels in pre-dialysis CRF patients and those undergoing regular haemodialysis against healthy controls.

Main Methods:

• A comparative study involving 35 pre-dialysis CRF patients, 35 haemodialysis patients, and 35 healthy controls.
• Serum levels of squamous cell antigen (SCC), CA 19.9, CA 125, carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and prostate-specific antigen (PSA) were measured.

Main Results:

• Elevated serum levels of SCC, CA 19.9, and CA 125 were observed in both pre-dialysis and haemodialysis patient groups compared to healthy controls.
• Serum levels of CEA, AFP, and PSA were not significantly different across the studied groups (CRF patients and controls).

Conclusions:

• SCC, CA 19.9, and CA 125 show potential as biomarkers in patients with chronic renal failure and uraemia.
• CEA, AFP, and PSA do not appear to be significantly affected by chronic renal failure or haemodialysis in this cohort.